Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma

Yoshito Numata; Keiji Dohi; Ayako Furukawa; Shino Kikuoka; Hidehisa Asada; Takahiro Fukunaga; Yasushi Taniguchi; Kazuyuki Sasakura; Tetsuo Tsuji; Ken Inouye; Michihiro Yoshimura; Hiroshi Itoh; Masashi Mukoyama; Hirofumi Yasue; Kazuwa Nakao

doi:10.1093/clinchem/44.5.1008

Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma

Yoshito Numata, Keiji Dohi, Ayako Furukawa, Shino Kikuoka, Hidehisa Asada, Takahiro Fukunaga, Yasushi Taniguchi, Kazuyuki Sasakura, Tetsuo Tsuji, Ken Inouye, Michihiro Yoshimura, Hiroshi Itoh, Masashi Mukoyama, Hirofumi Yasue, Kazuwa Nakao

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Recently, the N-terminal fragment of proatrial natriuretic peptide (N- terminal proANP) has been proposed as a marker of chronic congestive heart failure. In this study, we established a two-step immunoradiometric assay using monoclonal antibodies and synthetic N-terminal proANP (1-67) as a standard. It allows us to measure plasma N-terminal proANP in only 4 h without prior extraction. The detection limit of this assay was 15 pmol/L for a 100 μL sample of plasma. Within-run CVs ranged from 1.7% to 2.9% and between-run CVs ranged from 4.2% to 5.1%. The dilution curves of plasma samples showed good linearity and analytical recovery was 89-104%. The mean (±SD) N-terminal proANP in plasma of 33 healthy subjects was 188 (±71) pmol/L and 1030 (±411) pmol/L in 25 patients with heart failure. Our immunoradiometric assay is rapid and precise enough for routine determination of N-terminal proANP in human plasma.

Original language	English
Pages (from-to)	1008-1013
Number of pages	6
Journal	Clinical Chemistry
Volume	44
Issue number	5
DOIs	https://doi.org/10.1093/clinchem/44.5.1008
Publication status	Published - 1998
Externally published	Yes

ASJC Scopus subject areas

Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/clinchem/44.5.1008

Cite this

Numata, Y., Dohi, K., Furukawa, A., Kikuoka, S., Asada, H., Fukunaga, T., Taniguchi, Y., Sasakura, K., Tsuji, T., Inouye, K., Yoshimura, M., Itoh, H., Mukoyama, M., Yasue, H., & Nakao, K. (1998). Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. Clinical Chemistry, 44(5), 1008-1013. https://doi.org/10.1093/clinchem/44.5.1008

Numata, Y, Dohi, K, Furukawa, A, Kikuoka, S, Asada, H, Fukunaga, T, Taniguchi, Y, Sasakura, K, Tsuji, T, Inouye, K, Yoshimura, M, Itoh, H, Mukoyama, M, Yasue, H & Nakao, K 1998, 'Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma', Clinical Chemistry, vol. 44, no. 5, pp. 1008-1013. https://doi.org/10.1093/clinchem/44.5.1008

@article{34fc7c06285140a99bedd0d06dcc9f67,

title = "Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma",

abstract = "Recently, the N-terminal fragment of proatrial natriuretic peptide (N- terminal proANP) has been proposed as a marker of chronic congestive heart failure. In this study, we established a two-step immunoradiometric assay using monoclonal antibodies and synthetic N-terminal proANP (1-67) as a standard. It allows us to measure plasma N-terminal proANP in only 4 h without prior extraction. The detection limit of this assay was 15 pmol/L for a 100 μL sample of plasma. Within-run CVs ranged from 1.7% to 2.9% and between-run CVs ranged from 4.2% to 5.1%. The dilution curves of plasma samples showed good linearity and analytical recovery was 89-104%. The mean (±SD) N-terminal proANP in plasma of 33 healthy subjects was 188 (±71) pmol/L and 1030 (±411) pmol/L in 25 patients with heart failure. Our immunoradiometric assay is rapid and precise enough for routine determination of N-terminal proANP in human plasma.",

author = "Yoshito Numata and Keiji Dohi and Ayako Furukawa and Shino Kikuoka and Hidehisa Asada and Takahiro Fukunaga and Yasushi Taniguchi and Kazuyuki Sasakura and Tetsuo Tsuji and Ken Inouye and Michihiro Yoshimura and Hiroshi Itoh and Masashi Mukoyama and Hirofumi Yasue and Kazuwa Nakao",

year = "1998",

doi = "10.1093/clinchem/44.5.1008",

language = "English",

volume = "44",

pages = "1008--1013",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry Inc.",

number = "5",

}

TY - JOUR

T1 - Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma

AU - Numata, Yoshito

AU - Dohi, Keiji

AU - Furukawa, Ayako

AU - Kikuoka, Shino

AU - Asada, Hidehisa

AU - Fukunaga, Takahiro

AU - Taniguchi, Yasushi

AU - Sasakura, Kazuyuki

AU - Tsuji, Tetsuo

AU - Inouye, Ken

AU - Yoshimura, Michihiro

AU - Itoh, Hiroshi

AU - Mukoyama, Masashi

AU - Yasue, Hirofumi

AU - Nakao, Kazuwa

PY - 1998

Y1 - 1998

N2 - Recently, the N-terminal fragment of proatrial natriuretic peptide (N- terminal proANP) has been proposed as a marker of chronic congestive heart failure. In this study, we established a two-step immunoradiometric assay using monoclonal antibodies and synthetic N-terminal proANP (1-67) as a standard. It allows us to measure plasma N-terminal proANP in only 4 h without prior extraction. The detection limit of this assay was 15 pmol/L for a 100 μL sample of plasma. Within-run CVs ranged from 1.7% to 2.9% and between-run CVs ranged from 4.2% to 5.1%. The dilution curves of plasma samples showed good linearity and analytical recovery was 89-104%. The mean (±SD) N-terminal proANP in plasma of 33 healthy subjects was 188 (±71) pmol/L and 1030 (±411) pmol/L in 25 patients with heart failure. Our immunoradiometric assay is rapid and precise enough for routine determination of N-terminal proANP in human plasma.

AB - Recently, the N-terminal fragment of proatrial natriuretic peptide (N- terminal proANP) has been proposed as a marker of chronic congestive heart failure. In this study, we established a two-step immunoradiometric assay using monoclonal antibodies and synthetic N-terminal proANP (1-67) as a standard. It allows us to measure plasma N-terminal proANP in only 4 h without prior extraction. The detection limit of this assay was 15 pmol/L for a 100 μL sample of plasma. Within-run CVs ranged from 1.7% to 2.9% and between-run CVs ranged from 4.2% to 5.1%. The dilution curves of plasma samples showed good linearity and analytical recovery was 89-104%. The mean (±SD) N-terminal proANP in plasma of 33 healthy subjects was 188 (±71) pmol/L and 1030 (±411) pmol/L in 25 patients with heart failure. Our immunoradiometric assay is rapid and precise enough for routine determination of N-terminal proANP in human plasma.

UR - http://www.scopus.com/inward/record.url?scp=15444344202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444344202&partnerID=8YFLogxK

U2 - 10.1093/clinchem/44.5.1008

DO - 10.1093/clinchem/44.5.1008

M3 - Article

C2 - 9590374

AN - SCOPUS:15444344202

VL - 44

SP - 1008

EP - 1013

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 5

ER -

Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this